
|Videos|March 6, 2014
Potential Biomarkers in Prostate Cancer
Author(s)Leonard Gomella, MD
Leonard Gomella, MD, chair, Department of Urology, director, Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses the future of biomarkers in prostate cancer that might complement or displace PSA.
Advertisement
Leonard Gomella, MD, chair, Department of Urology, director, Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses the future of biomarkers in prostate cancer that might complement or displace PSA.
Clinical Pearls:
- There are a large number of genomic markers being looked at such as specific genetic alterations in circulating tumor cells
- These potential biomarkers are still being researched but are providing prognostic information and genomic information
- Although many biomarkers are being researched, none yet have the potential to displace PSA
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
2
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
3
Roxadustat Granted Orphan Drug Designation for Myelodysplastic Syndromes
4
FDA Fast-Tracks Muzastotug Combo in MSS Metastatic Colorectal Cancer
5










































